[A case responding to weekly paclitaxel (TXL) therapy as third line chemotherapy for scirrhous type gastric cancer].
A 67-year-old female was admitted to our hospital in May, 2001 for examination. She was diagnosed with advanced gastric cancer that was inoperable due to peritoneal dissemination. Seventeen courses of sequential MTX and 5-FU therapy, and 2 courses of TS-1 plus CDDP were carried out. A partial response (PR) and prolonged NC were obtained after these chemotherapies. However, pleural effusion and ascites appeared again, and we diagnosed progressive disease. As a third line chemotherapy for this patient, paclitaxel (TXL) was administered. Treatment consisted of two 3-week courses of paclitaxel 70 mg per m2 on day 1 of each week, with a 1-week break between the courses. Two weeks after the start of this therapy, pleural effusion and ascites had completely disappeared. Paclitaxel is considered to be promising for advanced gastric cancers, as second or third line chemotherapy with paclitaxel for patients with inoperable gastric cancer seems to be effective in improving QOL.
Sagawa
Tamotsu
T
Dept. of Internal Medicine, Higashi-Sapporo Hospital.
Tsuji
Yasushi
Y
Takayanagi
Norihiro
N
Hirayama
Yasuo
Y
Sakamaki
Sumio
S
Chiba
Hiroki
H
Nakajima
Takaharu
T
Iyama
Satoshi
S
Oku
Takatomi
T
Sumiyoshi
Tetsuya
T
Sato
Yasushi
Y
Takahashi
Minoru
M
Takayama
Tetsuji
T
Niitsu
Yoshiro
Y
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D010996:Pleural Effusion / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel